Frazier Healthcare Partners Acquires MatrixCare
Frazier Healthcare PartnersAcquirer
MatrixCareTarget
Frazier Healthcare Partners has agreed to acquire MatrixCare, the post‑acute electronic health record platform owned by ResMed, for an undisclosed price, with closing expected in the first quarter of FY2027 pending regulatory approval.
Frazier Healthcare Partners announced on July 8, 2026 that it will acquire MatrixCare, the electronic health‑record (EHR) suite serving hospice, home health, skilled‑nursing and senior‑living providers. The transaction value was not disclosed, and the deal is slated to close in the first quarter of Frazier’s fiscal year 2027, subject to customary regulatory clearances.
Deal Terms
The acquisition includes MatrixCare’s core EHR platform as well as the branded solutions Healthcare First and Citus, which together address both home‑based and facility‑based care settings. ResMed, the global medical‑technology company that currently owns MatrixCare, will divest the business as part of a broader portfolio‑rebalancing effort. Frazier, a Seattle‑based private‑equity firm with roughly 180 prior acquisitions, will take MatrixCare private and intends to fund product‑development initiatives through its capital base.
Strategic Rationale
MatrixCare occupies a niche in the post‑acute care market where specialized workflow automation and outcome‑tracking tools are increasingly valued. By adding the platform to its health‑tech portfolio, Frazier gains a recurring‑revenue SaaS asset with deep penetration in a fragmented segment. The firm’s statement highlighted an aggressive investment plan to accelerate innovation, suggesting a focus on expanding functionality such as tele‑health integration and AI‑driven clinical decision support.
ResMed’s decision to sell aligns with its stated intent to concentrate on high‑growth, sleep‑health technologies and AI‑centric digital solutions. The divestiture frees capital that can be redeployed toward its core sleep‑apnea devices and related software, which the company believes offer higher scalability.
Industry observers note that the move underscores the continued appetite of health‑care‑focused private equity for niche SaaS platforms that deliver sticky, high‑margin recurring revenue. For MatrixCare’s existing customer base, the change of ownership is expected to bring additional resources for product upgrades without disrupting day‑to‑day operations.
Why It Matters
For MatrixCare, the acquisition provides a dedicated financial backer with a track record of scaling health‑tech SaaS businesses, which should translate into accelerated product road‑maps and potentially broader market reach. Competitors such as Epic’s post‑acute modules and Cerner’s home‑health solutions may face heightened pressure as MatrixCare leverages Frazier’s capital to deepen integration and add advanced analytics features.
ResMed, by exiting the post‑acute EHR space, can sharpen its focus on sleep‑health devices and AI‑driven platforms that align with its long‑term growth narrative. This reallocation of capital may enable faster rollout of next‑generation sleep‑therapy technologies, strengthening its competitive position against firms like Philips Respironics and Invacare.
Key Points
- Frazier Healthcare Partners agreed to acquire MatrixCare from ResMed for an undisclosed amount.
- The deal is expected to close in Q1 of FY2027, subject to regulatory approval.
- MatrixCare’s portfolio includes the Healthcare First and Citus brands serving hospice, home health, skilled‑nursing and senior‑living providers.
- ResMed is divesting MatrixCare to concentrate on sleep‑health and AI‑centric growth opportunities.
- Frazier has completed roughly 180 acquisitions since 1991, emphasizing health‑care SaaS assets.
Analysis
While the purchase price was not disclosed, private‑equity buyers typically value post‑acute SaaS platforms at 8‑12 times trailing twelve‑month revenue, reflecting the high retention rates and low churn inherent in provider‑centric contracts. Assuming MatrixCare’s ARR falls within the $150‑$250 million range, the implied valuation would be in the $1.2‑$3.0 billion band, a range that aligns with recent PE activity in health‑tech. The transaction signals that investors remain confident in the scalability of niche SaaS solutions that address regulatory‑driven quality metrics and reimbursement models in the post‑acute space. For operators, the deal underscores the importance of building deep integrations and data‑analytics capabilities that can be leveraged by a PE owner to drive margin expansion. For SaaS investors, it reinforces the thesis that specialized, high‑margin health‑tech platforms continue to attract capital even as broader macro‑economic conditions tighten, provided they demonstrate strong net‑revenue retention and a clear path to product‑led growth.